Cargando…
Vonoprazan-based triple and dual therapy versus bismuth-based quadruple therapy for Helicobacter pylori infection in China: a three-arm, randomised clinical trial protocol
BACKGROUND: Helicobacter pylori infection and associated diseases are a growing global public health issue. H. pylori infection is the major cause of gastric cancer, over 90% of duodenal ulcers, and over 70% of gastric ulcers. The infection rate of H. pylori is approximately 50%, and approximately 5...
Autores principales: | Han, ShaoWei, Deng, ZiJie, Cheung, KaShing, Lyu, Tao, Chan, PuiLing, Li, Ying, Ni, Li, Luo, XiaPeng, Li, Kuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10329349/ https://www.ncbi.nlm.nih.gov/pubmed/37420205 http://dx.doi.org/10.1186/s12876-023-02872-7 |
Ejemplares similares
-
Evaluation of safety and pharmacokinetics of bismuth‐containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication
por: Huh, Ki Young, et al.
Publicado: (2021) -
14-Day Vonoprazan-Based Bismuth Quadruple Therapy for Treatment-Naïve Patients with Helicobacter pylori Infection: A Retrospective Comparative Study
por: Lu, Feifei, et al.
Publicado: (2023) -
Susceptibility-guided bismuth quadruple therapies for resistant Helicobacter pylori infections
por: Yang, Tiankuo, et al.
Publicado: (2020) -
Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori
por: Gisbert, Javier P, et al.
Publicado: (2012) -
Effect of gastric microbiota on quadruple Helicobacter pylori eradication therapy containing bismuth
por: Niu, Zhan-Yue, et al.
Publicado: (2021)